Notably, several drugs that primarily target cancer-related pathways, such as PI3K-AKT inhibitors (Alpelisib, Ipatasertib, Taselisib), VEGFR antagonists (Cediranib), mTORC1/2 inhibitors (Afuresertib), and CDK inhibitors (Tozasertib), demonstrate this effect. This evidence concerns the gene AKT1 and cancer.